Can-Fite BioPharma Ltd. (AMEX:CANF)’s traded shares stood at 0.3 million during the last session. At the close of trading, the stock’s price was $1.49, to imply a decrease of -2.61% or -$0.04 in intraday trading. The CANF share’s 52-week high remains $4.39, putting it -194.63% down since that peak but still an impressive 0.67% since price per share fell to its 52-week low of $1.48. The company has a valuation of $25.62M, with an average of 0.14 million shares in intraday trading volume over the past 10 days and average of 154.95K shares over the past 3 months.
Analysts have given a consensus recommendation of a Buy for Can-Fite BioPharma Ltd. (CANF), translating to a mean rating of 2.00. Of 2 analyst(s) looking at the stock, 0 analyst(s) give CANF a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 2 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -$0.1.
Can-Fite BioPharma Ltd. (AMEX:CANF) trade information
After registering a -2.61% downside in the last session, Can-Fite BioPharma Ltd. (CANF) has traded red over the past five days. The stock hit a weekly high of 1.6400 this Friday, 10/08/21, dropping -2.61% in its intraday price action. The 5-day price performance for the stock is -9.15%, and -16.29% over 30 days. With these gigs, the year-to-date price performance is -16.29%. Short interest in Can-Fite BioPharma Ltd. (AMEX:CANF) saw shorts transact 0.3 million shares and set a 1.54 days time to cover.
Analysts on Wall Street suggest a consensus price target of $7.00, implying an increase of 78.71% to the stock’s current value. The extremes give us $5.00 and $9.00 for target low and target high price respectively. As such, CANF has been trading -504.03% off suggested target high and -235.57% from its likely low.
Can-Fite BioPharma Ltd. (CANF) estimates and forecasts
Looking at statistics comparing Can-Fite BioPharma Ltd. share performance against respective industry, we note that the company has outperformed competitors. Can-Fite BioPharma Ltd. (CANF) shares are -35.22% down over the last 6 months, with its year-to-date growth rate higher than industry average at 60.83% against 17.50%. Revenue is forecast to grow 66.70% this quarter before jumping 62.50% for the next one. The rating firms project that company’s revenue will shrink -16.10% compared to the previous financial year.
Revenue forecast for the current quarter as set by 3 analysts is $120k. Meanwhile, for the quarter ending Sep 2021, a total of 3 analyst(s) estimate revenue growth to $150k.Earnings reports from the last fiscal year show that sales brought in $204k and $211k respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to fall -41.20% before dropping -28.90% in the following quarter.
Can-Fite BioPharma Ltd. has its next earnings report out in November. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. Can-Fite BioPharma Ltd. has a forward dividend ratio of 0, with the share yield ticking at 0.00% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 0.00%.
Can-Fite BioPharma Ltd. (AMEX:CANF)’s Major holders
Can-Fite BioPharma Ltd. insiders hold 1.07% of total outstanding shares, with institutional holders owning 12.40% of the shares at 12.54% float percentage. In total, 12.40% institutions holds shares in the company, led by Cetera Advisor Networks LLC. As of Mar 30, 2021, the company held over 0.16 million shares (or 0.93% of shares), all amounting to roughly $0.4 million.
The next major institution holding the largest number of shares is Morgan Stanley with 79873.0 shares, or about 0.46% of shares outstanding. As of the market price on Mar 30, 2021, these shares were worth $0.2 million.